Lysosomal damage is a therapeutic target in Duchenne muscular dystrophy
Science Advances · 24.10.2025 · 11 (43)
DOI: 10.1126/sciadv.adv6805 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 24.10.2025. Verfasst von Abbass Jaber und 21 weiteren Autor:innen. Beteiligte Einrichtung: Généthon, 91000 Evry, France. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Lysosomes. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Duchenne muscular dystrophy (DMD), a muscle degenerative disease affecting young boys, arises from the loss of dystrophin. Current gene therapy approaches aim to restore a shortened form of dystrophin (microdystrophin) via adeno-associated vector delivery. While recent clinical studies show promise, therapeutic efficacy remains incomplete, emphasizing the need for improved approaches. Here, we identified lysosomal perturbations in myofibers of patients with DMD and animal models, an overlooked mechanism of cellular damage in muscular dystrophies. These were notably marked by the up-regulation and recruitment of Galectin-3, a biomarker of lysosomal membrane permeabilization, to lysosomes, alongside alterations in lysosome number, morphology, and function. Microdystrophin therapy in Dmd mdx mice fails to fully correct these damages. However, combining it with trehalose, a lysosome-protective disaccharide, substantially improves the outcome, enhancing muscle function, myopathology, and transcriptome. These findings highlight lysosomal damage as an important pathomechanism in DMD and suggest that combining trehalose with gene therapy could enhance therapeutic efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Généthon, 91000 Evry, France.
- Université Paris-Saclay, Univ. Evry, INSERM, Généthon, INTEGRARE research unit UMR_S951, 91000 Evry-Courcouronnes, France.
- Ecole Pratique des Hautes Etudes, PSL Research University, Sorbonne Université, INSERM, CRSA, 75012 Paris, France.
- Univ. Paris-Est Créteil, INSERM U955 IMRB, Ecole Nationale Vétérinaire d'Alfort, EFS, IMRB, Team BNMS, Maisons-Alfort, France.
- Muscle Pathology Unit, Institut de Myologie and Neuropathology Department, Sorbonne Université, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.
- Mondor Institute of Biomedical Research, University of Paris Est Créteil, INSERM U955, Créteil, France.
ORCID-Profile: Abbass Jaber, Laura Palmieri, Nathalie Bourg, Ai Vu Hong, Elise Lachiver, Carinne Roudaut, Sonia Albini, Daniel Stockholm, Guillaume Tanniou, Nathalie Danièle, Inès Barthélémy, Mai Thao Bui, Teresinha Evangelista, Isabelle Richard, David Israeli
Zitieren
APA
Jaber, A., Palmieri, L., Bakour, R., Bourg, N., Hong, A. V., Lachiver, E., Roudaut, C., Poupiot, J., Albini, S., Stockholm, D., Van Wittenberghe, L., Miranda, A., Tanniou, G., Danièle, N., Barthélémy, I., Blot, S., Bui, M. T., Das, B., Malfatti, E., …, & Israeli, D. (2025). Lysosomal damage is a therapeutic target in Duchenne muscular dystrophy. Science Advances, 11(43). https://doi.org/10.1126/sciadv.adv6805
Vancouver
Jaber A, Palmieri L, Bakour R, Bourg N, Hong AV, Lachiver E, et al. Lysosomal damage is a therapeutic target in Duchenne muscular dystrophy. Science Advances. 2025;11(43). doi:10.1126/sciadv.adv6805
BibTeX
@article{Jaber2025,
author = {Jaber, Abbass and Palmieri, Laura and Bakour, Rania and Bourg, Nathalie and Hong, Ai Vu and Lachiver, Elise and Roudaut, Carinne and Poupiot, Jérôme and Albini, Sonia and Stockholm, Daniel and Van Wittenberghe, Laetitia and Miranda, Adeline and Tanniou, Guillaume and Danièle, Nathalie and Barthélémy, Inès and Blot, Stephane and Bui, Mai Thao and Das, Bornale and Malfatti, Edoardo and Evangelista, Teresinha and Richard, Isabelle and Israeli, David},
title = {Lysosomal damage is a therapeutic target in Duchenne muscular dystrophy},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {43},
doi = {10.1126/sciadv.adv6805}
}
EUVIMED